Side effects of therapy of hepatitis C and their managementFRIED, Michael W.Hepatology (Baltimore, Md.). 2002, Vol 36, Num 5, pp S237-S244, issn 0270-9139, SUP1Conference Paper

Side effects of therapy for chronic hepatitis CRUSSO, Mark W; FRIED, Michael W.Gastroenterology (New York, NY. 1943). 2003, Vol 124, Num 6, pp 1711-1719, issn 0016-5085, 9 p.Article

Persistent Portosystemic Shunts After Liver Transplantation Causing Episodic Hepatic EncephalopathyBARRITT IV, A. Sidney; FRIED, Michael W; HAYASHI, Paul H et al.Digestive diseases and sciences. 2010, Vol 55, Num 6, pp 1794-1798, issn 0163-2116, 5 p.Article

Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?EVON, Donna M; FRIED, Michael W; GOLIN, Carol E et al.Journal of consulting and clinical psychology. 2013, Vol 81, Num 2, pp 361-374, issn 0022-006X, 14 p.Article

Unexpected Maintenance of Hepatitis C Viral Diversity following Liver TransplantationGRAY, Rebecca R; STRICKLAND, Samantha L; VERAS, Nazle M et al.Journal of virology. 2012, Vol 86, Num 16, pp 8432-8439, issn 0022-538X, 8 p.Article

The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 ActivitySCHRIEBER, Sarah J; ZHIMING WEN; VOURVAHIS, Manoli et al.Drug metabolism and disposition. 2008, Vol 36, Num 9, pp 1909-1916, issn 0090-9556, 8 p.Article

Hepatic gene expression during treatment with peginterferon and ribavirin : Identifying molecular pathways for treatment responseFELD, Jordan J; NANDA, Santosh; FRIED, Michael W et al.Hepatology (Baltimore, Md.). 2007, Vol 46, Num 5, pp 1548-1563, issn 0270-9139, 16 p.Article

Social stigmatization and hepatitis C virus infectionZACKS, Steven; BEAVERS, Kimberly; THEODORE, Dickens et al.Journal of clinical gastroenterology. 2006, Vol 40, Num 3, pp 220-224, issn 0192-0790, 5 p.Article

Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle ExtractZHIMING WEN; DUMAS, Todd E; SCHRIEBER, Sarah J et al.Drug metabolism and disposition. 2008, Vol 36, Num 1, pp 65-72, issn 0090-9556, 8 p.Article

Assessing the validity of self-reported medication adherence in hepatitis C treatmentSMITH, Scott R; WAHED, Abdus S; KELLEY, Stephanie S et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 7-8, pp 1116-1123, issn 1060-0280, 8 p.Article

Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infectionPARSONS, Thomas D; TUCKER, Karen A; HALL, Colin D et al.AIDS (London). 2006, Vol 20, Num 12, pp 1591-1595, issn 0269-9370, 5 p.Article

Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis CTHEODORE, Dickens; SHIFFMAN, Mitchell L; NOLTE, Frederick S et al.Digestive diseases and sciences. 2003, Vol 48, Num 1, pp 140-145, issn 0163-2116, 6 p.Article

Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis CRAJENDER REDDY, K; WRIGHT, Teresa L; LEE, William M et al.Hepatology (Baltimore, Md.). 2001, Vol 33, Num 2, pp 433-438, issn 0270-9139Article

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialJACOBSON, Ira M; DORE, Gregory J; OUWERKERK-MAHADEVAN, Sivi et al.Lancet (British edition). 2014, Vol 384, Num 9941, pp 403-413, issn 0140-6736, 11 p.Article

A Randomized Controlled Trial of an Integrated Care I ntervention to Increase Eligibility for Chronic Hepatitis C TreatmentEVON, Donna M; SIMPSON, Kelly; KIXMILLER, Scott et al.The American journal of gastroenterology. 2011, Vol 106, Num 10, pp 1777-1786, issn 0002-9270, 10 p.Article

Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis CSCHRIEBER, Sarah J; HAWKE, Roy L; DOO, Edward et al.Drug metabolism and disposition. 2011, Vol 39, Num 12, pp 2182-2190, issn 0090-9556, 9 p.Article

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionFRIED, Michael W; SHIFFMAN, Mitchell L; CRAXI, Antonio et al.The New England journal of medicine. 2002, Vol 347, Num 13, pp 975-982, issn 0028-4793Article

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40kd)LEE, Samuel S; HEATHCOTE, E. Jenny; PAPPAS, Stephen C et al.Journal of hepatology. 2002, Vol 37, Num 4, pp 500-506, issn 0168-8278, 7 p.Article

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CBRONOWICKI, Jean-Pierre; POL, Stanislas; HEZODE, Christophe et al.Antiviral therapy (London). 2013, Vol 18, Num 7, pp 885-893, issn 1359-6535, 9 p.Article

Quantitation of Pretreatment Serum Interferon-γ―Inducible Protein-10 Improves the Predictive Value of an IL28B Gene Polymorphism for Hepatitis C Treatment ResponseDARLING, Jama M; AERSSENS, Jeroen; TALLOEN, Willem et al.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 1, pp 14-22, issn 0270-9139, 9 p.Article

Ribavirin Potentiates Interferon Action by Augmenting Interferon-Stimulated Gene Induction in Hepatitis C Virus Cell Culture ModelsTHOMAS, Emmanuel; FELD, Jordan J; QISHENG LI et al.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 1, pp 32-41, issn 0270-9139, 10 p.Article

Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus RibavirinREAU, Nancy; HADZIYANNIS, Stephanos J; MESSINGER, Diethelm et al.The American journal of gastroenterology. 2008, Vol 103, Num 8, pp 1981-1988, issn 0002-9270, 8 p.Article

Improved Outcomes in Patients with Hepatitis C with Difficult-to-Treat Characteristics : Randomized Study of Higher Doses of Peginterferon α-2a and RibavirinFRIED, Michael W; JENSEN, Donald M; KA WANG et al.Hepatology (Baltimore, Md.). 2008, Vol 48, Num 4, pp 1033-1043, issn 0270-9139, 11 p.Article

High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbiditiesEVON, Donna M; VERMA, Amit; DOUGHERTY, Karen A et al.Digestive diseases and sciences. 2007, Vol 52, Num 11, pp 3251-3258, issn 0163-2116, 8 p.Article

Hepatitis C and alcohol: Fundamental and translational research directionsMORGAN, Timothy R; BRENNER, David; LUCAS, Diane L et al.Alcoholism, clinical and experimental research. 2003, Vol 27, Num 4, pp 726-731, issn 0145-6008, 6 p.Article